Preoperative Embolization of Arteriovenous Malformations with Polylene Threads: Techniques with Wing Microcatheter and Pathologic Results

The technique with a wing microcatheter system and the pathologic aspects of 11 cerebral arteriovenous malformations (AVMs) surgically resected after embolization with polylene threads are reported. Embolization was performed once in eight patients and twice in three patients. Resected AVMs were submitted both to routine hematoxylin-eosin examination and to immunohistochemical workup in order to detect the type of immunologic response to thread emboli. In nine cases, 50% or more of the nidus was obliterated by the embolization. After embolization two patients developed reversible neurologic deficits. Pathologic specimens of resected AVMs demonstrated no vascular necrosis; however, a moderate inflammatory response could be seen, characterized by the presence of both mononuclear cells and foreign-body giant cells, associated with the absence of polymorphonuclear infiltrates. A granulomatous fibrotic process was identified that was present from the first month after embolization. Immunohistochemistry indicated that the immunologic response to thread emboli was cell-mediated, not humoral.

Embolization with the wing microcatheter with the use of polylene threads proved to be a safe and efficient system of embolization, as a preoperative procedure. Polylene threads are a nontoxic and biocompatible material that can be used as an embolic agent for brain AVMs.

Endovascular surgery carried out by interventionalists in specialized centers is now an effective therapeutic tool, both as a preoperative auxiliary procedure and, in selected cases, as the sole method of treatment. However, in the field of brain arteriovenous malformations (AVMs), present techniques cannot be considered fully satisfactory and many problems still persist. Dissatisfaction with both balloon catheter systems (risks of arterial rupture and vasospasm [1, 2]) and the impossibility of particulate embolization) and the most widely used embolic agent, bucrylate (abrupt solidification within the angioma, difficult calculation of the proper polymerization time [3], possible immediate or delayed hemorrhage after the embolization [4], and disappointing pathologic findings in resected specimens of previously embolized AVMs [5, 6]), led us to search for new and safer alternative materials of catheterization and embolization.

This article deals with our new microcatheter system and with the pathologic aspects of cerebral AVMs surgically resected after embolization with polylene threads.

Materials and Methods

Embolization Technique

Our technique is a modification of the Debrun balloon catheter system [7], with the distal end of the Silastic microcatheter completely open and exposed. To prepare this catheter a No. 17 latex balloon is put on a 2.5-French Silastic microcatheter.* The tip of the balloon is then cut so that the tips of the microcatheter and balloon are aligned and the distal end of the Silastic microcatheter is completely exposed. With fine microsurgery forceps, five vertical

* Ingenor, Paris, France.
cuts are made on the walls of the balloon surrounding the catheter as far as its neck. At the end of the procedure, five small latex wings have been created around the tip of the catheter (Fig. 1). These "floating" wings increase the area exposed to the bloodstream, and consequently the traction of the microcatheter along the direction of blood flow is strengthened [8, 9].

Intravascular navigation is flow-dependent and is obtained by a propulsion chamber. The microcatheter is slipped into an outer 6-French polyethylene coaxial catheter.1 Once the microcatheter has reached the desired position, superselective angiograms of the vascular feeders are obtained without blocking the blood flow, similar to the system of Rufenacht and Merland [1, 2]. Manual injections of 1–2 ml of contrast medium1 are adequate, with digital subtraction angiographic equipment, to obtain reliable maps of the AVM and its feeders. As embolic agents, both fluids and particles can be used with our multipurpose microcatheter; therefore, it is suitable both for AVM embolization and for injection of chemotherapeutic agents. We have used the wing microcatheter for isobutyl 2-cyanoacrylate (IBCA) delivery, but our experience is based mainly on the use of threads, which can be injected through this catheter as well as through other ones (Pursil® or Tracker®). Polyfilament polyethylene 3–0 threads (0.2 mm in diameter)2 cut 1.5–2 mm long are fitted into 22-gauge catheter needles3 loaded (five emboli each) before the embolization procedure and ready for use. The loaded catheter needle is connected to a 2.5-ml syringe and inserted into the proximal end of the microcatheter. Emboli are then discharged into the artery by 1.5–2 ml of saline. The great majority of threads reach the nidus of the AVM, and a progressive embolization is achieved under continuous angiographic control and neurologic observation in the alert patient. Because this technique results in a progressive embolization, the higher-flow shunts are the first to close, followed by the slower-flow ones. Only when shunt flow is markedly reduced, at the very end of the procedure, can a few threads be deposited on the walls of the arterial pedicles, very close to the AVM. At the end of each procedure, superselective angiography of the embolized feeder is carried out by means of the same microcatheter.

Once one feeder is embolized, the same microcatheter can be moved to other feeders, without the need for complete withdrawal; in this way, many pedicles can be embolized in the same session. Control angiograms with the outer coaxial polyethylene catheter are obtained at the end of each embolization, and, if necessary, angiography during various phases of the procedure can be performed without removing the microcatheter.

Patient Population

Forty-two patients with symptomatic brain AVMs underwent 54 embolization procedures carried out with our wing microcatheter. The indication for embolization was the presence of a "critical" (or "eloquent") AVM, defined as a vascular malformation adjacent to or within critical areas of the brain for which surgical removal alone could result in possible permanent neurologic damage [10, 11]. History of a previous hemorrhage was an important criterion for the procedure.

Clinical status was tested before and after embolization. For each embolization the estimated amount of nidus obliteration was recorded.

On the basis of the results of embolization, the patients then underwent surgery or radiosurgery or were scheduled for further embolization sessions.

Pathology

The tissues were fixed in 10% formalin and embedded in paraffin. From each block 5-μm-thick sections were obtained for routine hematoxylin-eosin examination and for immunohistochemistry. In evaluating morphologic changes of vascular walls secondary to embolization with polyethylene thread, we excluded those produced by refractile foreign particles commonly introduced in AVMs during cerebral angiography [12].

Immunohistochemistry.—To characterize the nature of inflammatory cells eventually present around polyethylene threads, we analyzed immunohistochemically the paraffin sections obtained for routine hematoxylin-eosin examination. Every section had been treated with a series of antibodies reactive in routinely fixed paraffin-embedded tissue, including LN1, MB2, UCHL1, and antivimentin antibodies, that discriminate between B and T lymphocytes and recognize fibroblasts. Specifically, LN1 [13] is a murine monoclonal antibody of IgM class.

1 PBN, Soeborg, Denmark.
2 Iopamiro 300, Bracco Industria Chimica, Milan, Italy.
3 Bait, Montmocey, France.
4 Target Therapeutics, Los Angeles, CA.
5 Howmedica, Hamburg, W. Germany.
6 Venflon 2 Viggo, Helsingborg, Sweden.
directed against a cell-surface sialoantigen. In lymph nodes LN1 was found to have a remarkable specificity for germinal center cells and a weak reaction in the B-cell mantle zones. Within germinal centers it stained all cells with the exception of macrophages. MB2 [14] is a murine monoclonal antibody of IgG1 subclass that recognizes a neuroaminidase-resistant 28-kd antigen, strongly expressed in the cytoplasm of B cells and weakly on T cells. UCHL1 is an IgG2a murine monoclonal antibody that recognizes a 185-kd determinant on T cells, some macrophages, and polymorphonuclear (PMN) leukocytes [15]. Vimentin is the predominant intermediate filament of mesenchymal cells, first characterized in chick embryo fibroblasts [16]. It is regularly present in fibroblasts and their derived neoplasms, as well as in nevus cells, malignant melanomas [17], and hemopoietic cells [18]. Mouse antisera LN1 and MB2 were obtained from Biotest Diagnostic, **tt Biotest Diagnostic, Frank furt, W. Germ any. Dako, Glostrup, Denmark. Sigma Chemical Co., St. Louis, Mo.

**tt Biotest Diagnostic, Frank furt, W. German y.
**tt Dako, Glostrup, Denmark.
**tt Behring, Frankfurt, W. Germany.
**tt Sigma Chemical Co., St. Louis, Mo.

**tt Biotest Diagnostic, Frank furt, W. Germany.
**tt Dako, Glostrup, Denmark.
**tt Behring, Frankfurt, W. Germany.
**tt Sigma Chemical Co., St. Louis, Mo.

Embolization was performed only once in eight patients and twice in three. In nine patients 50% or more of the nidus was obliterated by the embolization. The interval between embolization(s) and surgery ranged from 4 to 50 weeks.

Intracranial navigation with the wing microcatheter failed twice. Only two complications, totally reversible, minor deficits, were noticed with our microcatheter and embolization with threads (homonymous hemianopia completely resolved in 1 day in both cases). No deaths or permanent neurologic deficits were observed with our technique.

In all cases in which a significant decrease (50% or more) in the size of the AVM was obtained (nine of 11), the surgeon believed that preoperative embolization had considerably helped the surgical removal of the angioma, which would have been very risky in five cases without prior embolization. Surgery caused two neurologic deficits (one quadrantanopia and one homonymous hemianopia) that persisted 4–6 months later. In one patient seizures significantly worsened; in another, homonymous hemianopia from previous bleeding persisted unmodified. The seven remaining patients were completely normal at postoperative follow-ups 6 months after the operation.

**Pathologic

Among the 11 resected AVMs previously embolized with threads, eight AVMs (cases 1–8) embolized only once were considered of particular interest because we attempted to establish a sequence of histopathologic events chronologically related to the embolization. The AVMs in this subgroup were resected 4–30 weeks after the last embolization with threads.

Routine sections of AVMs showed polylene threads in a varying, but frequently small, number of vascular channels. The threads appeared as a colorless material, birefringent in polarized light, and when seen together in multiple fascicles, mimicked a beehive in transverse sections (Fig. 4).

In tissues examined beginning at 6 weeks after embolization therapy, every polylene fiber was surrounded by varying amounts of granulation tissue, with a rich component of mononuclear cells, spindle-shaped cells, and foreign-body giant cells interspersed with many small capillary vessels.

The mononuclear inflammatory infiltrate consistently diminished in tissues resected 12 weeks or more after embolization. After this time the polylene threads were surrounded by a thin cushion of connective tissue with a few mononuclear inflammatory cells and foreign-body giant cells that filled and completely occluded the vascular lumen. In only one vessel (case 7) was a cleft seen between the vascular wall and this connective cushion (Fig. 5).

Necrosis of vascular channel walls was never found, nor were threads discovered in the neuroglial parenchyma that commonly lies in the interstices of the vascular channels. In four cases (cases 1–3 and 5), aggregates of PMN infiltrates were present in the wall of some AVM channels, but only in case 1 were a few leukocytes seen around the polylene threads. In the other three cases (cases 2, 3, and 5), PMN infiltrates were far from the thread emboli.
Immunohistochemistry.—Immunohistochemical methods permitted us to characterize the mononuclear infiltrate, previously described. Around polyethylene fibers we always found a great number of T lymphocytes, UCHL1-positive (Fig. 6), and a variable number of spindle-shaped vimentin-positive fibroblasts. We never found any LN1- and MB2-positive cells, markers of B lymphocytes.

Discussion

In therapeutic embolization of spinal, head and neck, and intracranial vascular abnormalities, embolization techniques have included particulate embolizations and balloon detachments. Various proposed techniques for embolization of brain AVMs have proved unsatisfactory, and as a result a “gold standard” of proved efficacy and safety does not exist.

Recently, various authors have tried to avoid the risks of vascular damage (overdistension, hemorrhage, vasoconstriction) linked to the inflation of the balloon attached to the tip of the microcatheter [1, 2]. Above all, many questions exist concerning the best embolic agent for clinical use. Bucrylate, being fluid, would have the ideal properties for use in embolotherapy of cerebral AVMs, and various other substances [22, 23] are under evaluation (Strother CM and Hilal SK, personal communications). Bucrylate is still the most common embolic agent for this type of disease [3, 7, 24–27]. Nevertheless, many problems arise as to both its practical use and its long-term consequences. Regarding its practicality, the abrupt solidification of IBCA in the AVM vasculature and the complicated calculation of the right polymerization time make progressive embolization impossible. Furthermore, the catheter has to be withdrawn as soon as possible to avoid “in situ” gluing. Not infrequently the arterial feeder or the venous outlets are blocked, with possibly unfavorable clinical consequences. Regarding the long-term pathologic changes induced by bucrylate, we totally agree with Vinters et al. [4]: “It is important to know the fate of a substance that will persist in human tissues for months or years.”

Long-term pathologic follow-up of brain AVMs treated by embolization with bucrylate has shown patchy transmural necrosis of portions of vessels treated days or weeks before with IBCA embolotherapy [5, 28]. The discovery of extravas-
Fig. 2 (E–H).—Case 3 (cont.).
E and F, After embolization of second feeder (posterior parietal artery), small part of AVM fed by posterior temporal branch still persists. In oblique view (F) this feeder appears too narrow to be selectively catheterized (arrows).
G and H, Postoperative control angiograms show complete resection of AVM.

Fig. 3.—Case 7.
A, Medium-sized left posterior parietal arteriovenous malformation (AVM) fed by angular and posterior parietal arteries.
B, Final angiogram after embolization with wing microcatheter and polylene threads of dilated angular artery. Significant decrease of both AVM size and embolized feeder.
C, Postoperative control angiogram. Complete resection of AVM.
<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age</th>
<th>Gender</th>
<th>Location of AVM</th>
<th>Previous Hemorrhage</th>
<th>Clinical Status</th>
<th>No. of Embolizations (% Occlusion)</th>
<th>Interval Between Embolization and Surgery (weeks)</th>
<th>Mononuclear Cells</th>
<th>Giant Cells</th>
<th>Fibrosis</th>
<th>Polymorphonuclear Infiltrate</th>
<th>Postoperative Follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>36</td>
<td>F</td>
<td>R parieto-occipital</td>
<td>Yes</td>
<td>L homonymous hemianopia</td>
<td>No changes</td>
<td>1 (50)</td>
<td>4</td>
<td>Rare</td>
<td>Present</td>
<td>Absent</td>
<td>Rare</td>
</tr>
<tr>
<td>2</td>
<td>42</td>
<td>M</td>
<td>L temporal</td>
<td>No</td>
<td>Seizures</td>
<td>Normal</td>
<td>1 (50)</td>
<td>5</td>
<td>Rare</td>
<td>Present</td>
<td>Present</td>
<td>Present far from emboli</td>
</tr>
<tr>
<td>3</td>
<td>35</td>
<td>M</td>
<td>L temporal-parietal</td>
<td>No</td>
<td>Seizures</td>
<td>Normal</td>
<td>1 (70)</td>
<td>5</td>
<td>Rare</td>
<td>Present</td>
<td>Present</td>
<td>Present far from emboli</td>
</tr>
<tr>
<td>4</td>
<td>37</td>
<td>F</td>
<td>R occipital</td>
<td>No</td>
<td>Headaches</td>
<td>L homonymous hemianopia resolved in 1 day</td>
<td>1 (75)</td>
<td>6</td>
<td>Rare</td>
<td>Conspicuous</td>
<td>Present</td>
<td>Normal (6)</td>
</tr>
<tr>
<td>5</td>
<td>32</td>
<td>F</td>
<td>R occipital</td>
<td>No</td>
<td>Headaches</td>
<td>L homonymous hemianopia resolved in 1 day</td>
<td>1 (80)</td>
<td>6</td>
<td>Rare</td>
<td>Present</td>
<td>Present</td>
<td>Present far from emboli</td>
</tr>
<tr>
<td>6</td>
<td>32</td>
<td>F</td>
<td>L frontal</td>
<td>No</td>
<td>Seizures, headaches</td>
<td>Normal</td>
<td>1 (40)</td>
<td>12</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>7</td>
<td>45</td>
<td>M</td>
<td>L parietal</td>
<td>Yes</td>
<td>Seizures</td>
<td>Normal</td>
<td>1 (60)</td>
<td>18</td>
<td>Present</td>
<td>Present</td>
<td>Conspicuous</td>
<td>Absent</td>
</tr>
<tr>
<td>8</td>
<td>10</td>
<td>M</td>
<td>R parietal</td>
<td>No</td>
<td>Headaches</td>
<td>Normal</td>
<td>1 (95)</td>
<td>30</td>
<td>Absent</td>
<td>Present</td>
<td>Conspicuous</td>
<td>Absent</td>
</tr>
<tr>
<td>9</td>
<td>49</td>
<td>M</td>
<td>L temporal</td>
<td>Yes</td>
<td>Normal</td>
<td>Normal</td>
<td>2 (90)</td>
<td>22, 6</td>
<td>Present</td>
<td>Conspicuous</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>10</td>
<td>23</td>
<td>M</td>
<td>L frontal</td>
<td>No</td>
<td>Seizures</td>
<td>Normal</td>
<td>2 (45)</td>
<td>12, 8</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>11</td>
<td>36</td>
<td>M</td>
<td>R parietal</td>
<td>No</td>
<td>Seizures</td>
<td>Normal</td>
<td>2 (85)</td>
<td>50, 25</td>
<td>Rare</td>
<td>Present</td>
<td>Conspicuous</td>
<td>Absent</td>
</tr>
</tbody>
</table>

Note.—Vessel wall necrosis was absent in all patients.
cular bucrylate within the neuroglial parenchyma would speak in favor of its possible migration from the intravascular compartment. Delayed hemorrhage after therapeutic embolization with bucrylate can be explained partly by this mechanism [4].

In this report the pathologic changes observed in cerebral AVMs embolized with polylene threads and surgically resected 4 weeks to 1 year later are described. The hallmarks of the inflammatory response to polylene threads are the presence of both mononuclear cells and foreign-body giant cells and the absence of PMN infiltrates.

The presence or absence of PMN infiltrates is very important because it is the only reproducible parameter that is used to evaluate the presence or absence of wall necrosis. In fact, as the AVM is, by definition, a lesion in which there is a variable amount of elastica from vessel to vessel [29], the destruction of this imperfect elastica by the inflammatory reaction cannot be assessed accurately [28]. Thus, we considered the classical histochemical stains for the components of vascular wall to be inappropriate (trichrome, Weigert's for elastin, or silver impregnation for reticulin). Similarly, experimental studies on the effects of any embolizing material in normal cerebral vessels may have relatively little to contribute to settling this specific issue [5].

Differing from what has been reported for IBCA [4–6, 28], we found PMN infiltrates in the vascular wall close to polylene threads only in one patient (case 1). The AVM in this patient was resected at the shortest interval after embolization (4 weeks). This finding would speak in favor of a release of PMN chemotactic factors soon after embolization. However, we did not find this response to extend beyond 4 weeks. Vascular necrosis associated with PMN infiltrates was never found in the pathologic specimens of the remaining patients who underwent surgery 5–50 weeks after the embolization. In three other patients (cases 2, 3, and 5), PMN infiltrates were present in the wall of AVM channels far from the thread emboli. This inflammatory reaction may have occurred in response to necrosis, which may in turn have been a function of occlusion of the major blood supply to the AVM, similar to resected AVMs after balloon embolizations, in which no embolic substance was injected [30].

Another important factor that should be stressed is the phenomenon of revascularization. This well-known event, frequently observed during inflammation also, is confirmed by "in vitro" studies in which lymphocytes, macrophages, platelets, prostaglandin E, collagen, and products of cellular rexis [31, 32] are seen. In all patients examined, highly vascularized granulation tissue was observed surrounding polylene threads (Fig. 4). In our opinion, these small capillary vessels are not able to reestablish the AVM nidus. However in case 7, where the AVM was excised 4 months after embolization, a C-shaped cleft was seen between the thread emboli enveloped by endothelium and the fibrosclerotic wall of only one partially obstructed artery. Viable-appearing RBCs could also be seen. This finding suggests that threads adhere to the endothelium of vessels that are larger than the emboli. Adherence is noted, particularly at sites of turbulence in branching vessels or in vessels with high vascular flow. Similar phenomena were also reported to occur with other embolic agents [4, 22, 33]. On the other hand, as long as a tissue remains viable it will have a blood supply [33]; therefore, a tissue made ischemic and fibrotic by therapeutic embolization, but which still remains viable, will reestablish, to some degree, its blood supply. Our more recent leaning is toward shorter intervals between embolization and surgery in order to avoid the occurrence both of recanalization and of the hemodynamic changes caused by redistribution of blood flow within AVM vasculature.

In human tissue the analysis of cellular population and in particular of lymphocytes has been greatly facilitated by the availability of monoclonal antibodies directed against specific cellular antigens and against lymphoid differentiation antigens. However, until recently, cryostat sections have been required because most lymphoid antigens have not survived conventional fixation and processing. This has imposed a serious limitation on the study of lymphocyte activities in inflammatory and neoplastic tissues, since most routine histologic tissues arrive at the laboratory in fixative. Recently, a new generation
of monoclonal antibodies has been described that are capable of assigning a B-cell or T-cell derivation to a lymphoid population in fixed tissues. The antibodies LN1 [13] and MB2 [14] recognize epitopes on normal and neoplastic B cells. The monoclonal antibody UCHL1 shows specificity for cells of T-cell derivation [34], and the well-known antimunin antibody reacts with this protein expressed by fibroblasts.

The application of this panel of antibodies to embolized AVMs allowed us to investigate the sequence of pathogenetic events related to the presence of polylene threads within AVM vasculature. The absence of LN1- and MB2-positive cells around polylene threads permitted us to state that B lymphocytes are not involved in this inflammatory process; in other words, the immunologic process occurring in response to this type of foreign substance is not a humoral one. On the contrary, many UCHL1-positive T lymphocytes and vimentin-positive fibroblasts are present. As in other better known granulomatous inflammatory responses, we can postulate T lymphocytes produce lymphokines-activating macrophages that synthesize interleukin 1 and fibronectin [35]. Interleukin 1 again activates T lymphocytes and fibronectin promotes fibroblast recruitment, attachment, and proliferation in the granulomas [36]. The final result would be a self-maintaining process reaching the fibrotic stage.

Embolization by means of our microcatheter system with polylene threads proved to be a useful and reliable tool to achieve, in conjunction with surgery, complete cure in a significant number of critical AVMs.

Morbidity and technical failures are both so low as to justify the embolization as the first step in the treatment plan of the majority of critical AVMs. Pathologic studies of brain AVMs resected after embolization have demonstrated the absence of angiogenesis. A moderate inflammatory response can be seen that tends to be alleviated by the fourth week.

The immunologic response to thread emboli is cell-mediated, not humoral. It gives origin to a self-maintaining granulomatous-fibrotic process, which begins after the first month and peaks at the third month. The threads used in our procedures are nonreabsorbable, biocompatible, nontoxic, and useful as embolizing agents for brain AVMs.

REFERENCES


15. Smith SH, Brown MH, Rowe D, Callard RE, Beverley PCL. Functional subset on human helper-inducer cells defined by a new monoclonal antibo-

dy, UCHL1. Immunology 1986;55:63–70
24. Kerber C. Intracranial cyanocrylate: a new catheter therapy for arterio-

venous malformation. Invest Radiol 1975;10:536–538
25. Cromwell LD, Harris AB. Treatment of cerebral arteriovenous malforma-

tions. A combined neurological and neuroradiological approach. J Neu-

rosurg 1980;52:705–708
26. Drake CG. Arteriovenous malformations of the brain. The option for manage-

28. Vinters HV, Debrun G, Kaufmann JC, Drake CG. Pathology of arterio-

30. Mannma TM, Martin NA, Vinters HV. The pathology of encephalic arterio-

venous malformations treated by prior embolotherapy. Neurology 1980;30:1–10
34. Norton J, Ramsay AD, Smith SH, Beverley PCL, Isaacson PG. Mono-